因编辑、细胞治疗与RNA技术前沿报告行业现状（英）
Gene, Cell, & RNA Therapy Q2 2025 Quarterly Data Report Key takeaways from Q2 2025
报告摘要
Gene, Cell, & RNA Therapy Q2 2025 Quarterly Data Report Key takeaways from Q2 2025
报告信息
- 文件全名
- 《因编辑、细胞治疗与RNA技术前沿报告行业现状（英）-41页.pdf》
- 适合读者
- 核心数据
- the 80 gene therapy trials initiated in Q2, 64% are for oncology indications, the highest proportion
- 76% were for non-oncology indications. In the RNA therapy pipeline, 38 trials were initiated in Q2, up
- from 35 last quarter, of which 74% were for non-oncology indications.
- Acquisitions of CGT assets continue to increase quarter by quarter, with a 33% jump in volume,
- 核心议题
常见问题
《因编辑、细胞治疗与RNA技术前沿报告行业现状（英）》主要包含哪些内容?
Gene, Cell, & RNA Therapy Q2 2025 Quarterly Data Report Key takeaways from Q2 2025核心数据:the 80 gene therapy trials initiated in Q2, 64% are for oncology indications, the highest proportion;76% were for non-oncology indications. In the RNA therapy pipeline, 38 trials were initiated in Q2, up;from 35 last quarter, of which 74% were for non-oncology indications.。
这份报告覆盖哪一年、篇幅多大?
覆盖 2025 年,全文约 41。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合战略规划、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了细胞治疗等议题。
继续阅读
查看全部 →